Teva Pharmaceutical Industries (TEVA) News Today

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares were slightly lower despite a series of favorable neuroscience updates presented at Psych Congress. The news strengthens Teva’s innovative-drug pipeline, but the benefits are largely clinical and may not immediately translate into revenue.

• Positive Sentiment: UZEDY real-world data support commercial momentum. Teva reported that UZEDY improved treatment adherence and persistence in schizophrenia compared with other long-acting injectables. Patients also had fewer emergency-room visits and hospitalizations, while estimated direct healthcare savings exceeded $1,000 per patient per month. In bipolar I disorder, patients switching to UZEDY had a lower treatment-failure rate than those remaining on oral antipsychotics. UZEDY real-world data
• Positive Sentiment: TEV-'749 data bolster the pipeline ahead of an FDA decision. In a post hoc analysis of the Phase 3 SOLARIS trial, 56% of participants achieved stabilization, only 4% of stabilized patients relapsed, and 21% of those treated for at least six months met remission criteria. The once-monthly olanzapine injection could improve adherence versus daily oral treatment, with an FDA decision expected in the fourth quarter of 2026. TEV-'749 SOLARIS data
• Positive Sentiment: AUSTEDO appears aligned with physician priorities. A study of 489 healthcare professionals found that drowsiness risk, short-term symptom improvement, drug interactions and long-term response data were key factors in tardive dyskinesia treatment selection. AUSTEDO was the most closely aligned option across the patient profiles studied, potentially supporting prescriptions for Teva’s established neuroscience portfolio. AUSTEDO physician-preference study
• Neutral Sentiment: The UZEDY and TEV-'749 findings were company-sponsored presentations and include observational or post hoc analyses, so their commercial impact remains dependent on physician adoption, reimbursement and regulatory approval.
• Negative Sentiment: TEV-'749 remains investigational and could fail to receive FDA approval. In addition, reported insider activity shows selling rather than buying by Teva executives, which may temper investor enthusiasm even as institutional ownership has been mixed.